Imx 110

Drug Profile

Imx 110

Alternative Names: Imx-110

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immix Biopharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA intercalators; NF-kappa B inhibitors; Protein tyrosine kinase inhibitors; STAT3 transcription factor inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 15 Feb 2018 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Australia (Parenteral) (NCT03382340)
  • 05 Jan 2018 Pharmacodynamics data from a preclinical trial in pancreatic cancer released by Immix Biopharma
  • 24 Dec 2017 Immix Biopharma plans a first-in-human phase I/IIa trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in January 2018 (NCT03382340)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top